Skip to main content

Table 1 Antihypertensive therapy at baseline and during follow-up

From: Irbesartan for the treatment of hypertension in patients with the metabolic syndrome: A sub analysis of the Treat to Target post authorization survey. Prospective observational, two armed study in 14,200 patients

   Baseline after switch after 3 month after 9 month
   Metab (-) Metab (+) Metab (-) Metab (+) Metab (-) Metab (+) Metab (-) Metab (+)
Substance classes          
none % 4.9 2.7 0.0 0.0 0.0 0.0 0.0 0.0
ACE-inhibitors % 48.2 59.3* 3.7 7.7* 3.5 7.6* 3.5 7.0*
Alpha-blockers % 3.2 4.1** 1.6 2.6* 1.5 2.6* 1.5 2.6*
ARBs % 4.0 4.7 98.9 99.8* 97.6 97.7 91.9 92.0
Beta-blockers % 44.3 49.3* 25.9 34.8* 25.3 33.7* 24.2 31.3*
Diuretics % 30.7 47.8* 7.0 14.4* 6.5 13.6* 6.0 12.4*
Calcium antagonists % 27.5 36.4* 13.3 22.7* 13.4 23.0* 13.0 21.8*
Irbesartan 75 mg % < 0.1 0.0 0.3 0.2 0.3 0.1** 0.3 0.1**
Irbesartan 150 mg % 0.5 0.4 11.0 5.8* 8.0 3.7* 7.5 3.2*
Irbesartan 300 mg % 0.1 0.2 29.8 22.0* 28.2 19.8* 25.2 17.9*
Irbesartan 150 mg/12,5 mg HCTZ % < 0.1 0.1 10.8 9.1** 8.9 6.6* 8.4 6.1*
Irbesartan 300 mg/12,5 mg HCTZ % 0.1 < 0.1 46.0 62.1* 50.4 66.0* 48.2 62.6*
  1. Met (+) – Patients with the metabolic syndrome (doctors' diagnosis); Met (-) – Patients without the metabolic syndrome; statistical test applied: Chi2-test; * p < 0.0001 vs. patients without MS; ** p < 0.01 vs. patients without MS